| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ian M Hastings | |
| P433 | issue | 11 | |
| P921 | main subject | antimalarial | Q521616 |
| P304 | page(s) | 512-518 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Trends in Parasitology | Q15265846 |
| P1476 | title | The origins of antimalarial drug resistance | |
| P478 | volume | 20 |
| Q30483123 | A database of antimalarial drug resistance |
| Q28540567 | A population genetic model for the initial spread of partially resistant malaria parasites under anti-malarial combination therapy and weak intrahost competition |
| Q36075783 | Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness. |
| Q35385310 | Amplification of pfmdr1, pfcrt, pvmdr1, and K13 propeller polymorphisms associated with Plasmodium falciparum and Plasmodium vivax isolates from the China-Myanmar border |
| Q34044092 | An analytical model for genetic hitchhiking in the evolution of antimalarial drug resistance |
| Q36376756 | Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model |
| Q34735569 | Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites |
| Q35840784 | Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America |
| Q39055325 | Complex dynamics and stability of resistance to antimalarial drugs. |
| Q36971299 | Defining the origin of Plasmodium falciparum resistant dhfr isolates in Senegal |
| Q38118386 | Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race |
| Q43947607 | Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania |
| Q34058304 | Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports |
| Q35107675 | Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model |
| Q47100748 | Functional analysis of Plasmodium falciparum subpopulations associated with artemisinin resistance in Cambodia. |
| Q39055351 | Gametocytocidal activity in antimalarial drugs speeds the spread of drug resistance |
| Q38127840 | Genetic and genomic approaches for the discovery of parasite genes involved in antimalarial drug resistance |
| Q28478493 | High prevalence of drug resistance in animal trypanosomes without a history of drug exposure |
| Q36478207 | How antimalarial drug resistance affects post-treatment prophylaxis |
| Q37503352 | Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. |
| Q41502886 | In vitro synergistic effect of fluoroquinolone analogues in combination with artemisinin against Plasmodium falciparum; their antiplasmodial action in rodent malaria model |
| Q37721293 | Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review |
| Q35532863 | Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations |
| Q55878749 | Malaria |
| Q36832446 | Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development |
| Q21032492 | Malaria in the Greater Mekong Subregion: heterogeneity and complexity |
| Q39122575 | Malaria treatment using novel nano-based drug delivery systems |
| Q28475191 | Mapping the spread of malaria drug resistance |
| Q28067367 | Mathematical Modelling to Guide Drug Development for Malaria Elimination |
| Q35890202 | Multiplicity of Infection and Disease Severity in Plasmodium vivax |
| Q36172400 | Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro |
| Q39489910 | Pharmacokinetic determinants of the window of selection for antimalarial drug resistance |
| Q37685088 | Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough? |
| Q37215608 | Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model. |
| Q36538998 | Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach. |
| Q36108352 | Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda |
| Q33892979 | Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. |
| Q39363372 | Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies |
| Q34596571 | Structure of the MTIP-MyoA complex, a key component of the malaria parasite invasion motor |
| Q33308734 | Structure of the scientific community modelling the evolution of resistance |
| Q57496665 | Synthesis and Study of the Antimalarial Cardamom Peroxide |
| Q41931529 | Synthesis and biological evaluation of some pyrazole derivatives as anti-malarial agents |
| Q33897315 | The dynamics of mutations associated with anti-malarial drug resistance in Plasmodium falciparum |
| Q35960963 | The skill and style to model the evolution of resistance to pesticides and drugs |
| Q41149881 | The threat of antimalarial drug resistance |
| Q41588963 | Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria |
Search more.